Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review
- PMID: 35874952
- PMCID: PMC9305266
- DOI: 10.7150/ijbs.73583
Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has undergone multiple mutations since its emergence, and its latest variant, Omicron (B.1.1.529), is the most contagious variant of concern (VOC) which poses a major and imminent threat to public health. Since firstly reported by World Health Organization (WHO) in November 2021, Omicron variant has been spreading rapidly and has become the dominant variant in many countries worldwide. Omicron is the most mutated variant so far, containing 60 mutations in its genome, including 37 mutations in the S-protein. Since all current COVID-19 vaccines in use were developed based on ancestral SARS-CoV-2 strains, whether they are protective against Omicron is a critical question which has been the center of study currently. In this article, we systemically reviewed the studies regarding the effectiveness of 2- or 3-dose vaccines delivered in either homologous or heterologous manner. The humoral and cellular immune responses elicited by various vaccine regimens to protect against Omicron variant are discussed. Current understanding of the molecular basis underlying immune escape of Omicron was also analyzed. These studies indicate that two doses of vaccination are insufficient to elicit neutralizing antibody responses against Omicron variant. Nevertheless, Omicron-specific humoral immune responses can be enhanced by booster dose of almost all type vaccines in certain degree, and heterologous vaccination strategy may represent a better choice than homogenous regimens. Intriguingly, results of studies indicate that all current vaccines are still able to elicit robust T cell response against Omicron. Future focus should be the development of Omicron variant vaccine, which may induce potent humoral as well as cellular immune responses simultaneously against all known variants of the SARS-CoV-2 virus.
Keywords: Omicron variant; SARS-COV-2; booster dose; humoral immune response, cellular immune response; vaccine.
© The author(s).
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Similar articles
-
Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.Microbiol Spectr. 2022 Oct 26;10(5):e0060922. doi: 10.1128/spectrum.00609-22. Epub 2022 Aug 25. Microbiol Spectr. 2022. PMID: 36005765 Free PMC article.
-
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.Elife. 2022 Aug 25;11:e78633. doi: 10.7554/eLife.78633. Elife. 2022. PMID: 36004719 Free PMC article.
-
Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study.J Infect Public Health. 2024 Jul;17(7):102473. doi: 10.1016/j.jiph.2024.102473. Epub 2024 Jun 7. J Infect Public Health. 2024. PMID: 38865774
-
A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant.Immunol Lett. 2022 Mar;243:38-43. doi: 10.1016/j.imlet.2022.02.002. Epub 2022 Feb 4. Immunol Lett. 2022. PMID: 35131373 Free PMC article. Review.
-
The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.Front Public Health. 2022 Jul 13;10:940956. doi: 10.3389/fpubh.2022.940956. eCollection 2022. Front Public Health. 2022. PMID: 35910897 Free PMC article.
Cited by
-
Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV.Front Immunol. 2023 Mar 2;14:1152695. doi: 10.3389/fimmu.2023.1152695. eCollection 2023. Front Immunol. 2023. PMID: 36936952 Free PMC article.
-
Assessment of immunoglobin G (spike and nucleocapsid protein) response to COVID-19 vaccination in Palestine.Clin Epidemiol Glob Health. 2023 Jul-Aug;22:101330. doi: 10.1016/j.cegh.2023.101330. Epub 2023 Jun 3. Clin Epidemiol Glob Health. 2023. PMID: 37293133 Free PMC article.
-
Antibody Profiling of Microbial Antigens in the Blood of COVID-19 mRNA Vaccine Recipients Using Microbial Protein Microarrays.Vaccines (Basel). 2023 Nov 7;11(11):1694. doi: 10.3390/vaccines11111694. Vaccines (Basel). 2023. PMID: 38006026 Free PMC article.
-
Influence of SARS-CoV-2 mRNA Vaccine Booster among Cancer Patients on Active Treatment Previously Immunized with Inactivated versus mRNA Vaccines: A Prospective Cohort Study.Vaccines (Basel). 2023 Jul 3;11(7):1193. doi: 10.3390/vaccines11071193. Vaccines (Basel). 2023. PMID: 37515009 Free PMC article.
-
Evaluation of Cellular Immune Responses After mRNA-1273 Vaccination in Children 6 Months to 11 Years of Age.J Infect Dis. 2025 Jun 2;231(5):e945-e955. doi: 10.1093/infdis/jiaf144. J Infect Dis. 2025. PMID: 40119775 Free PMC article. Clinical Trial.
References
-
- Ghebreyesus TA. WHO Director-General's opening remarks at the 150th session of the Executive Board — 24 January 2022. 2022.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous